Literature DB >> 26551635

Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.

Celalettin Ustun1, Elizabeth L Courville2, Todd DeFor3, Michelle Dolan2, Nicole Randall4, Sophia Yohe2, Nelli Bejanyan4, Erica Warlick4, Claudio Brunstein4, Daniel J Weisdorf4, Michael A Linden2.   

Abstract

Stringent complete remission (CR) in acute myeloid leukemia (AML) requires the absence of both morphologic and flow cytometric evidence of disease. We have previously shown that persistent AML detected by flow cytometry (FC+) before reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT) was associated with significantly increased relapse, shorter disease-free survival (DFS), and poorer overall survival (OS), independent of morphologic blast count. We evaluated the effect of FC status on outcomes of alloHCT for AML after either myeloablative conditioning (MAC) or RIC regimens in 203 patients (MAC, n = 80, and RIC, n = 123) with no morphologic evidence of persistent AML pretransplant on marrow biopsy. The allografts included 130 umbilical cord blood (UCB) and 73 sibling donors. We performed central review of pretransplant standard sensitivity FC to identify detectable FC+. Twenty-five patients were FC+, including 15 (18.7%) receiving MAC and 10 (8.1%) RIC alloHCT. Among RIC patients FC+ was associated with significantly inferior relapse, DFS, and OS (multiple regression HR, 3.8; 95% CI, 1.7 to 8.7; P < .01 for relapse; HR, 2.9; 95% CI, 1.4 to 5.9; P < .01 for DFS; and HR, 3.4; 95% CI, 1.7 to 7; P < .01 for OS). In contrast, FC+ status was not associated with relapse or decreased OS after MAC. These data suggest that MAC, but not RIC, overcomes the negative effect of pretransplant FC+ after sibling or UCB alloHCT. Therefore, a deeper pretransplant leukemia-free state is preferred for those treated with RIC.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AML; Allogeneic hematopoietic cell transplantation; Complete remission; Flow cytometry; Myeloablative conditioning; Reduced-intensity conditioning; Relapse; Survival

Mesh:

Substances:

Year:  2015        PMID: 26551635      PMCID: PMC4805453          DOI: 10.1016/j.bbmt.2015.10.024

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  35 in total

1.  Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse.

Authors:  M Hoegh-Petersen; M A Amin; Y Liu; A Ugarte-Torres; T S Williamson; P J Podgorny; J A Russell; A Grigg; D Ritchie; J Storek
Journal:  Bone Marrow Transplant       Date:  2012-06-04       Impact factor: 5.483

2.  Effectiveness of dasatinib in accelerated-phase chronic myeloid leukemia with p190 BCR-ABL1 and a second Philadelphia chromosome.

Authors:  Karen E Rabenau; Michelle Dolan; Sophia Yohe; Celalettin Ustun
Journal:  Cancer Genet       Date:  2014-02-22

3.  Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood.

Authors:  Claudio G Brunstein; Jonathan A Gutman; Daniel J Weisdorf; Ann E Woolfrey; Todd E Defor; Theodore A Gooley; Michael R Verneris; Frederick R Appelbaum; John E Wagner; Colleen Delaney
Journal:  Blood       Date:  2010-08-04       Impact factor: 22.113

4.  Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia.

Authors:  Régis Peffault de Latour; Claudio G Brunstein; Raphael Porcher; Patrice Chevallier; Marie Robin; Erica Warlick; Alienor Xhaard; Celalettin Ustun; Jérôme Larghero; Nathalie Dhedin; Mohamad Mohty; Gerard Socié; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-18       Impact factor: 5.742

5.  Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.

Authors:  Michael Keeney; Jaimie G Halley; Daniel D Rhoads; M Qasim Ansari; Steven J Kussick; William J Karlon; Kumudini U Mehta; David M Dorfman; Michael A Linden
Journal:  Arch Pathol Lab Med       Date:  2015-02-19       Impact factor: 5.534

6.  Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML.

Authors:  F Bonifazi; G Bandini; D Rondelli; S Falcioni; M Stanzani; A Bontadini; P L Tazzari; M Arpinati; B Giannini; R Conte; M Baccarani
Journal:  Bone Marrow Transplant       Date:  2003-08       Impact factor: 5.483

7.  Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years.

Authors:  Karamjeet S Sandhu; Claudio Brunstein; Todd DeFor; Nelli Bejanyan; Mukta Arora; Erica Warlick; Daniel Weisdorf; Celalettin Ustun
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-28       Impact factor: 5.742

Review 8.  To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.

Authors:  C Ustun; H M Lazarus; D Weisdorf
Journal:  Bone Marrow Transplant       Date:  2013-05-06       Impact factor: 5.483

Review 9.  Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.

Authors:  S Fadilah Abdul Wahid; Nor-Azimah Ismail; Mohd-Razif Mohd-Idris; Fariza Wan Jamaluddin; NorRafeah Tumian; Ernie Yap Sze-Wei; Norasiah Muhammad; Ming Lai Nai
Journal:  Stem Cells Dev       Date:  2014-09-17       Impact factor: 3.272

10.  Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission.

Authors:  Rada M Grubovikj; Asif Alavi; Ahrin Koppel; Mary Territo; Gary J Schiller
Journal:  Cancers (Basel)       Date:  2012-06-20       Impact factor: 6.639

View more
  22 in total

1.  Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Authors:  Gheath Alatrash; Kelly M Kidwell; Peter F Thall; Antonio Di Stasi; Julianne Chen; Madhushree Zope; Alyssa K Crain; Richard E Champlin; Uday Popat; Elizabeth J Shpall; Roy B Jones; Borje S Andersson
Journal:  Bone Marrow Transplant       Date:  2018-12-10       Impact factor: 5.483

2.  Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD.

Authors:  Craig E Eckfeldt; Nicole Randall; Ryan M Shanley; Sophia Yohe; Nelli Bejanyan; Michelle Dolan; Erica D Warlick; Michael R Verneris; Claudio G Brunstein; John E Wagner; Daniel J Weisdorf; Celalettin Ustun
Journal:  Haematologica       Date:  2016-04-28       Impact factor: 9.941

Review 3.  Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia.

Authors:  Gaurav Goyal; Krishna Gundabolu; Saraschandra Vallabhajosyula; Peter T Silberstein; Vijaya Raj Bhatt
Journal:  Ther Adv Hematol       Date:  2016-04-22

4.  Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

Authors:  Celalettin Ustun; Soyoung Kim; Min Chen; Amer M Beitinjaneh; Valerie I Brown; Parastoo B Dahi; Andrew Daly; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Hillard M Lazarus; Taiga Nishihori; Richard F Olsson; Kristin M Page; Genovefa Papanicolaou; Ayman Saad; Sachiko Seo; Basem M William; John R Wingard; Baldeep Wirk; Jean A Yared; Miguel-Angel Perales; Jeffery J Auletta; Krishna V Komanduri; Caroline A Lindemans; Marcie L Riches
Journal:  Blood Adv       Date:  2019-09-10

5.  Molecular MRD status and outcome after transplantation in NPM1-mutated AML.

Authors:  Richard Dillon; Robert Hills; Sylvie Freeman; Nicola Potter; Jelena Jovanovic; Adam Ivey; Anju Shankar Kanda; Manohursingh Runglall; Nicola Foot; Mikel Valganon; Asim Khwaja; Jamie Cavenagh; Matthew Smith; Hans Beier Ommen; Ulrik Malthe Overgaard; Mike Dennis; Steven Knapper; Harpreet Kaur; David Taussig; Priyanka Mehta; Kavita Raj; Igor Novitzky-Basso; Emmanouil Nikolousis; Robert Danby; Pramila Krishnamurthy; Kate Hill; Damian Finnegan; Samah Alimam; Erin Hurst; Peter Johnson; Anjum Khan; Rahuman Salim; Charles Craddock; Ruth Spearing; Amanda Gilkes; Rosemary Gale; Alan Burnett; Nigel H Russell; David Grimwade
Journal:  Blood       Date:  2020-02-27       Impact factor: 22.113

6.  Minimal residual disease and stem cell transplantation outcomes.

Authors:  Jacqueline Cloos; Gert J Ossenkoppele; Richard Dillon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

7.  History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.

Authors:  Armin Rashidi; Michael A Linden; Todd E DeFor; Erica Warlick; Nelli Bejanyan; Sophia Yohe; Daniel J Weisdorf; Celalettin Ustun
Journal:  Am J Hematol       Date:  2017-07-29       Impact factor: 10.047

8.  Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.

Authors:  Joan How; Kiran R Vij; Maryam Ebadi; Todd E DeFor; Rizwan Romee; Michelle M Dolan; Celalettin Ustun; Daniel J Weisdorf; Michael A Linden; Armin Rashidi
Journal:  Am J Hematol       Date:  2018-10-09       Impact factor: 10.047

9.  Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.

Authors:  Betül Oran; Jeff L Jorgensen; David Marin; Sa Wang; Sairah Ahmed; Amin M Alousi; Borje S Andersson; Qaiser Bashir; Roland Bassett; Genevieve Lyons; Julianne Chen; Katy Rezvani; Uday Popat; Partow Kebriaei; Keyur Patel; Gabriela Rondon; Elizabeth J Shpall; Richard E Champlin
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

Review 10.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.

Authors:  P Tsirigotis; M Byrne; C Schmid; F Baron; F Ciceri; J Esteve; N C Gorin; S Giebel; M Mohty; B N Savani; A Nagler
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.